CA3213382A1 - Rifamycin analogs in combination with vancomycin and uses thereof - Google Patents

Rifamycin analogs in combination with vancomycin and uses thereof Download PDF

Info

Publication number
CA3213382A1
CA3213382A1 CA3213382A CA3213382A CA3213382A1 CA 3213382 A1 CA3213382 A1 CA 3213382A1 CA 3213382 A CA3213382 A CA 3213382A CA 3213382 A CA3213382 A CA 3213382A CA 3213382 A1 CA3213382 A1 CA 3213382A1
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
acceptable salt
vancomycin
compound
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3213382A
Other languages
English (en)
French (fr)
Inventor
Thomas Nittoli
Anna ZUMSTEG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CA3213382A1 publication Critical patent/CA3213382A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3213382A 2021-03-26 2022-03-25 Rifamycin analogs in combination with vancomycin and uses thereof Pending CA3213382A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163166597P 2021-03-26 2021-03-26
US63/166,597 2021-03-26
PCT/US2022/021922 WO2022204499A1 (en) 2021-03-26 2022-03-25 Rifamycin analogs in combination with vancomycin and uses thereof

Publications (1)

Publication Number Publication Date
CA3213382A1 true CA3213382A1 (en) 2022-09-29

Family

ID=81308077

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3213382A Pending CA3213382A1 (en) 2021-03-26 2022-03-25 Rifamycin analogs in combination with vancomycin and uses thereof

Country Status (14)

Country Link
US (1) US20240189319A1 (https=)
EP (1) EP4313060B1 (https=)
JP (1) JP2024511165A (https=)
KR (1) KR20230162654A (https=)
CN (1) CN117098540A (https=)
AU (1) AU2022246161A1 (https=)
BR (1) BR112023019720A2 (https=)
CA (1) CA3213382A1 (https=)
CL (1) CL2023002840A1 (https=)
CO (1) CO2023013406A2 (https=)
ES (1) ES3017798T3 (https=)
IL (1) IL307220A (https=)
MX (1) MX2023011328A (https=)
WO (1) WO2022204499A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024221162A1 (zh) * 2023-04-24 2024-10-31 丹诺医药(苏州）有限公司 化合物预防关节假体周围感染的方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260012505A (ko) 2024-07-18 2026-01-27 이화여자대학교 산학협력단 기계 학습을 이용한 반코마이신 초회 투여량 적합성 판단 시스템 및 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118955710A (zh) * 2018-05-09 2024-11-15 里珍纳龙药品有限公司 抗msr1抗体及其使用方法
PH12021551476A1 (en) * 2018-12-21 2022-04-25 Regeneron Pharma Rifamycin analogs and antibody-drug conjugates thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024221162A1 (zh) * 2023-04-24 2024-10-31 丹诺医药(苏州）有限公司 化合物预防关节假体周围感染的方法

Also Published As

Publication number Publication date
US20240189319A1 (en) 2024-06-13
CN117098540A (zh) 2023-11-21
BR112023019720A2 (pt) 2024-01-23
CO2023013406A2 (es) 2023-10-30
AU2022246161A1 (en) 2023-10-12
KR20230162654A (ko) 2023-11-28
ES3017798T3 (en) 2025-05-13
WO2022204499A1 (en) 2022-09-29
MX2023011328A (es) 2023-12-14
CL2023002840A1 (es) 2024-03-15
EP4313060A1 (en) 2024-02-07
IL307220A (en) 2023-11-01
JP2024511165A (ja) 2024-03-12
EP4313060B1 (en) 2025-03-05

Similar Documents

Publication Publication Date Title
CN101553470A (zh) 抗菌的喹啉衍生物
EP4313060B1 (en) Rifamycin analogs in combination with vancomycin and uses thereof
MX2013015079A (es) Compuestos que contienen nitrogeno y su uso.
JP5961177B2 (ja) 化合物及びその使用
CN108658991B (zh) 3,5-二取代甲基吡唑并[1,5-a]嘧啶-7-酚盐类似物和衍生物制备方法和用途
US11208387B2 (en) Macrocyclic broad spectrum antibiotics
WO2011113361A1 (zh) 头孢唑肟钠结晶水合物及其制备方法和用途
CN108368079A (zh) 治疗细菌感染的化合物及方法
CN105636966A (zh) 抗细菌铁载体-氨基青霉素缀合物
CN101232884A (zh) 作为抗菌剂的喹啉衍生物
JP2024073569A (ja) 亜鉛イオノフォアおよびその使用
CN105924456B (zh) 一种减少不良反应的头孢米诺钠化合物及其制剂
MXPA04011767A (es) COMPUESTOS UTILES EN EL TRATAMIENTO DE áNTRAX E INHIBIDORES DEL FACTOR LETAL.
WO2018045313A1 (en) Substituted urea depsipeptide analogs as activators of the clpp endopeptidase
CA2924733A1 (en) Aryl substituted aminomethyl spectinomycin analogs as antibacterial agents
HK40105351B (en) Rifamycin analogs in combination with vancomycin and uses thereof
HK40105351A (en) Rifamycin analogs in combination with vancomycin and uses thereof
CN101541752A (zh) 抗菌的喹啉衍生物
WO2018229141A1 (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of a disease involving gram-positive bacteria
CN117142940B (zh) 抗菌苯醌类衍生物、制备方法及应用
CN1315846C (zh) 7 －{ [ ( 5 －氨基 － 1 , 2 , 4 －噻二唑 － 3 －基 ) (氟代甲氧基亚氨基 )乙酰基 ]氨基} － 3 － [ (亚氨基 － 1－哌嗪基甲基 ) －甲基亚肼基 ] －甲基 －3 －头孢烯 － 4 －羧酸的结晶盐酸化物
US20250228841A1 (en) Compositions affecting pigment production and methods for treatment of bacterial diseases
CN119970732A (zh) 一种具有协同增效作用的抗菌组合物及其用途
CN103965051B (zh) 乙酰间苯三酚类化合物及其在制备抗菌药物中的应用
CN100451002C (zh) 2，6-二吡啶烯环己酮衍生物及其在制备抗菌药物中的应用

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250226

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250226